• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>World Journal of Hepatology >Advanced hepatocellular carcinoma responds to MK615 a compound extract from the Japanese apricot Prunus mume
【2h】

Advanced hepatocellular carcinoma responds to MK615 a compound extract from the Japanese apricot Prunus mume

机译：晚期肝细胞癌对日本杏梅花的复合提取物MK615有反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

MK615, a compound extracted from the Japanese apricot “Prunus mume” has been reported to have in vitro anti-tumor activities against several cancer cell lines, including hepatocellular carcinoma (HCC). However, the clinical effects and feasibility of administering MK615 for patients with HCC were unknown. We experienced a case with advanced HCC for which MK615 was effective against both lymph node and pulmonary metastases. A 60-year-old female underwent surgical resection of a 9 cm HCC in the right lobe. The pathological diagnosis was moderately differentiated HCC with vascular invasion. The HCC recurred in the liver 8 mo after the surgery. Radiofrequency ablation and transarterial infusion chemotherapy were performed, but the recurrence was not controlled. One year after the intrahepatic recurrence, pulmonary and lymph metastasis appeared. Sorafenib was administered, but was not effective. Then, MK615 was administered as a final alternative therapy after informed consent was obtained from the patient. Three months later, her alpha-fetoprotein level decrease and both the lymph node and pulmonary metastases decreased in size. The patient has survived for more than 17 mo after the MK615 administration, and was in good condition. Although further investigations are necessary to clarify its safety and efficacy in humans, MK615 may be useful for the treatment of HCC, without serious adverse effects.
机译：据报道，从日本杏“梅花”提取的化合物MK615具有针对多种癌细胞系（包括肝细胞癌（HCC））的体外抗肿瘤活性。但是，尚不清楚MK615对肝癌患者的临床疗效和可行性。我们经历了一个晚期肝癌病例，其中MK615对淋巴结转移和肺转移均有效。一名60岁的女性接受了右叶9 cm HCC的手术切除。病理诊断为中度肝癌伴血管侵犯。手术后8个月，肝癌在肝脏中复发。进行了射频消融和经动脉灌注化疗，但复发没有得到控制。肝内复发一年后，出现肺和淋巴转移。服用索拉非尼，但无效。然后，在获得患者知情同意后，将MK615作为最终的替代疗法进行管理。三个月后，她的甲胎蛋白水平下降，淋巴结和肺转移灶均缩小。服用MK615后，该患者存活了17个月以上，并且状况良好。尽管有必要进行进一步的研究以阐明其在人体中的安全性和有效性，但MK615可能对治疗HCC有用，而不会产生严重的不良反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号